{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:31:40Z","timestamp":1791433900372,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Lower-grade glioma (LGG) is rare among patients above the age of 60 (\u201celderly\u201d). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. This study set out to question this paradigm analyzing a contemporary cohort of patients with IDH mutant astrocytoma and oligodendroglioma WHO grade 2 and 3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Elderly patients treated in our department for a supratentorial, hemispheric LGG between 2009 and 2019 were retrospectively analyzed for patient-, tumor- and treatment-related factors and progression-free survival (PFS) and compared to patients aged under 60. Inclusion required the availability of subtype-defining molecular data and pre- and post-operative tumor volumes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>207 patients were included, among those 21 elderlies (10%). PFS was comparable between elderly and younger patients (46 <jats:italic>vs<\/jats:italic>. 54\u00a0months; p\u2009=\u20090.634). Oligodendroglioma was more common in the elderly (76% <jats:italic>vs<\/jats:italic>. 46%; p\u2009=\u20090.011). Most patients underwent tumor resection (elderly: 81% <jats:italic>vs<\/jats:italic>. younger: 91%; p\u2009=\u20090.246) yielding comparable residual tumor volumes (elderly: 7.8 cm<jats:sup>3<\/jats:sup>; younger: 4.1 cm<jats:sup>3<\/jats:sup>; p\u2009=\u20090.137). Adjuvant treatment was administered in 76% of elderly and 61% of younger patients (p\u2009=\u20090.163). Uni- and multi-variate survival analyses identified a tumor crossing the midline, surgical strategy, and pre- and post-operative tumor volumes as prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Elderly patients constitute a small fraction of molecularly characterized LGGs. In contrast to previous reports, favorable surgical and survival outcomes were achieved in our series comparable to those of younger patients. Thus, intensified treatment including maximal safe resection should be advocated in elderly patients whenever feasible.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-022-04230-1","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T11:39:53Z","timestamp":1673955593000},"page":"605-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort"],"prefix":"10.1007","volume":"161","author":[{"given":"P.","family":"Dao Trong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gluszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Reuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Herold-Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Unterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jungk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"4230_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"key":"4230_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro-Oncology"},{"key":"4230_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","volume":"120","author":"C Hartmann","year":"2010","unstructured":"Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707\u2013718. https:\/\/doi.org\/10.1007\/s00401-010-0781-z","journal-title":"Acta Neuropathol"},{"key":"4230_CR4","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, Cooper LAD, Rheinbay E, Miller CR, Vitucci M et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481\u20132498. https:\/\/doi.org\/10.1056\/NEJMoa1402121","journal-title":"N Engl J Med"},{"key":"4230_CR5","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1200\/JCO.2002.08.121","volume":"20","author":"F Pignatti","year":"2002","unstructured":"Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076\u20132084. https:\/\/doi.org\/10.1200\/JCO.2002.08.121","journal-title":"J Clin Oncol"},{"key":"4230_CR6","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.2011.35.8598","volume":"30","author":"EG Shaw","year":"2012","unstructured":"Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP (2012) Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 30:3065\u20133070. https:\/\/doi.org\/10.1200\/JCO.2011.35.8598","journal-title":"J Clin Oncol"},{"key":"4230_CR7","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","volume":"17","author":"BG Baumert","year":"2016","unstructured":"Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB et al (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17:1521\u20131532. https:\/\/doi.org\/10.1016\/S1470-2045(16)30313-8","journal-title":"Lancet Oncol"},{"key":"4230_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00401-009-0561-9","volume":"118","author":"C Hartmann","year":"2009","unstructured":"Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469\u2013474. https:\/\/doi.org\/10.1007\/s00401-009-0561-9","journal-title":"Acta Neuropathol"},{"key":"4230_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"4230_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.23736\/S0390-5616.19.04701-5","volume":"63","author":"RA Morshed","year":"2019","unstructured":"Morshed RA, Young JS, Hervey-Jumper SL, Berger MS (2019) The management of low-grade gliomas in adults. J Neurosurg Sci 63:450\u2013457. https:\/\/doi.org\/10.23736\/S0390-5616.19.04701-5","journal-title":"J Neurosurg Sci"},{"key":"4230_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11060-017-2439-3","volume":"133","author":"RS Youland","year":"2017","unstructured":"Youland RS, Schomas DA, Brown PD, Parney IF, Laack NNI (2017) Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience. J Neurooncol 133:339\u2013346. https:\/\/doi.org\/10.1007\/s11060-017-2439-3","journal-title":"J Neurooncol"},{"key":"4230_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11060-008-9669-3","volume":"90","author":"N Pouratian","year":"2008","unstructured":"Pouratian N, Mut M, Jagannathan J, Lopes MB, Shaffrey ME, Schiff D (2008) Low-grade gliomas in older patients: a retrospective analysis of prognostic factors. J Neurooncol 90:341\u2013350. https:\/\/doi.org\/10.1007\/s11060-008-9669-3","journal-title":"J Neurooncol"},{"key":"4230_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1212\/WNL.0b013e3181c6781e","volume":"73","author":"G Kaloshi","year":"2009","unstructured":"Kaloshi G, Psimaras D, Mokhtari K, Dehais C, Houillier C, Marie Y, Laigle-Donadey F, Taillibert S, Guillevin R, Martin-Duverneuil N et al (2009) Supratentorial low-grade gliomas in older patients. Neurology 73:2093\u20132098. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c6781e","journal-title":"Neurology"},{"key":"4230_CR14","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1002\/cncr.24444","volume":"115","author":"DA Schomas","year":"2009","unstructured":"Schomas DA, Laack NN, Brown PD (2009) Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer 115:3969\u20133978. https:\/\/doi.org\/10.1002\/cncr.24444","journal-title":"Cancer"},{"key":"4230_CR15","doi-asserted-by":"publisher","DOI":"10.15761\/icst.1000255","author":"P Kumthekar","year":"2017","unstructured":"Kumthekar P, Patel V, Bridge C, Rademaker A, Helenowski I, Mrugala MM, Rockhill JK, Grimm S, Swanson KR, Raizer J (2017) Prognosis of older patients with low-grade glioma: a retrospective study. Integr Cancer Sci Ther. https:\/\/doi.org\/10.15761\/icst.1000255","journal-title":"Integr Cancer Sci Ther"},{"key":"4230_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1750-3639.2009.00352.x","volume":"20","author":"D Capper","year":"2010","unstructured":"Capper D, Weissert S, Balss J, Habel A, Meyer J, J\u00e4ger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245\u2013254. https:\/\/doi.org\/10.1111\/j.1750-3639.2009.00352.x","journal-title":"Brain Pathol"},{"key":"4230_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00401-018-1879-y","volume":"136","author":"D Capper","year":"2018","unstructured":"Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, Schmid S, Hovestadt V, Reuss DE, Koelsche C et al (2018) Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol 136:181\u2013210. https:\/\/doi.org\/10.1007\/s00401-018-1879-y","journal-title":"Acta Neuropathol"},{"key":"4230_CR18","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462\u2013477. https:\/\/doi.org\/10.1016\/j.cell.2013.09.034","journal-title":"Cell"},{"key":"4230_CR19","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018. Neuro-Oncology 23:iii1\u2013iii105. https:\/\/doi.org\/10.1093\/neuonc\/noab200","journal-title":"Neuro-Oncology"},{"key":"4230_CR20","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS (2018) Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther 35:1763\u20131774. https:\/\/doi.org\/10.1007\/s12325-018-0805-y","journal-title":"Adv Ther"},{"key":"4230_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00401-015-1454-8","volume":"130","author":"DE Reuss","year":"2015","unstructured":"Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, Hovestadt V, Bewerunge-Hudler M, Jones DTW, Schittenhelm J et al (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130:407\u2013417. https:\/\/doi.org\/10.1007\/s00401-015-1454-8","journal-title":"Acta Neuropathol"},{"key":"4230_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/jnen\/nly012","volume":"77","author":"M Hasselblatt","year":"2018","unstructured":"Hasselblatt M, Jaber M, Reuss D, Grauer O, Bibo A, Terwey S, Schick U, Ebel H, Niederstadt T, Stummer W et al (2018) Diffuse astrocytoma, IDH-wildtype: a dissolving diagnosis. J Neuropathol Exp Neurol 77:422\u2013425. https:\/\/doi.org\/10.1093\/jnen\/nly012","journal-title":"J Neuropathol Exp Neurol"},{"key":"4230_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-0038-1636430","volume":"38","author":"A von Deimling","year":"2018","unstructured":"von Deimling A, Ono T, Shirahata M, Louis DN (2018) Grading of diffuse astrocytic gliomas: a review of studies before and after the advent of IDH testing. Semin Neurol 38:19\u201323. https:\/\/doi.org\/10.1055\/s-0038-1636430","journal-title":"Semin Neurol"},{"key":"4230_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","volume":"129","author":"A Olar","year":"2015","unstructured":"Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E et al (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II\u2013III diffuse gliomas. Acta Neuropathol 129:585\u2013596. https:\/\/doi.org\/10.1007\/s00401-015-1398-z","journal-title":"Acta Neuropathol"},{"key":"4230_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010122","author":"C Jungk","year":"2019","unstructured":"Jungk C, Warta R, Mock A, Friauf S, Hug B, Capper D, Abdollahi A, Debus J, Bendszus M, von Deimling A et al (2019) Location-dependent patient outcome and recurrence patterns in IDH1-wildtype glioblastoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11010122","journal-title":"Cancers (Basel)"},{"key":"4230_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11060-018-03044-4","volume":"141","author":"RA Morshed","year":"2019","unstructured":"Morshed RA, Han SJ, Hervey-Jumper SL, Pekmezci M, Troncon I, Chang SM, Butowski NA, Berger MS (2019) Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. J Neurooncol 141:383\u2013391. https:\/\/doi.org\/10.1007\/s11060-018-03044-4","journal-title":"J Neurooncol"},{"key":"4230_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","volume":"13","author":"W Wick","year":"2012","unstructured":"Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707\u2013715. https:\/\/doi.org\/10.1016\/S1470-2045(12)70164-X","journal-title":"Lancet Oncol"},{"key":"4230_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"4230_CR29","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/14737140.2020.1828867","volume":"20","author":"A Pellerino","year":"2020","unstructured":"Pellerino A, Bruno F, Intern\u00f2 V, Rud\u00e0 R, Soffietti R (2020) Current clinical management of elderly patients with glioma. Expert Rev Anticancer Ther 20:1037\u20131048. https:\/\/doi.org\/10.1080\/14737140.2020.1828867","journal-title":"Expert Rev Anticancer Ther"},{"key":"4230_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/neuonc\/not159","volume":"16","author":"J Beiko","year":"2014","unstructured":"Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS et al (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology 16:81\u201391. https:\/\/doi.org\/10.1093\/neuonc\/not159","journal-title":"Neuro-Oncology"},{"key":"4230_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/neuros\/nyy149","volume":"84","author":"PS Jones","year":"2019","unstructured":"Jones PS, Carroll KT, Koch M, DiCesare JAT, Reitz K, Frosch M, Barker FG, Cahill DP, Curry WT (2019) Isocitrate dehydrogenase mutations in low-grade gliomas correlate with prolonged overall survival in older patients. Neurosurgery 84:519\u2013528. https:\/\/doi.org\/10.1093\/neuros\/nyy149","journal-title":"Neurosurgery"},{"key":"4230_CR32","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1001\/jama.2012.12807","volume":"308","author":"AS Jakola","year":"2012","unstructured":"Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsg\u00e5rd G, Solheim O (2012) Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308:1881\u20131888. https:\/\/doi.org\/10.1001\/jama.2012.12807","journal-title":"JAMA"},{"key":"4230_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyz397","author":"M Scherer","year":"2019","unstructured":"Scherer M, Ahmeti H, Roder C, Gessler F, Jungk C, Pala A, Mayer B, Senft C, Tatagiba M, Synowitz M et al (2019) Surgery for diffuse WHO Grade II gliomas: volumetric analysis of a multicenter retrospective cohort from the German Study Group for Intraoperative Magnetic Resonance Imaging. Neurosurgery. https:\/\/doi.org\/10.1093\/neuros\/nyz397","journal-title":"Neurosurgery"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04230-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04230-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04230-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T09:13:02Z","timestamp":1678180382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04230-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["4230"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04230-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Medical Faculty of the University of Heidelberg (reference S-005\/2003, as of 31.01.2003).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}